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Abstract
Background: Acceptance of healthcare-associated pneumonia (HCAP) as an entity and the associated risk of
infection by potentially multidrug-resistant (MDR) organisms such as methicillin-resistant Staphylococcus aureus
(MRSA), Pseudomonas and Acinetobacter have been debated. We therefore compared patients with HCAP,
hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP) enrolled in a trial comparing
linezolid with vancomycin for treatment of pneumonia.
Methods: The analysis included all patients who received study drug. HCAP was defined as pneumonia
occurring < 48 hours into hospitalization and acquired in a long-term care, subacute, or intermediate health
care facility; following recent hospitalization; or after chronic dialysis.
Results: Data from 1184 patients (HCAP = 199, HAP = 379, VAP = 606) were analyzed. Compared with HAP and
VAP patients, those with HCAP were older, had slightly higher severity scores, and were more likely to have
comorbidities. Pseudomonas aeruginosa was the most common gram-negative organism isolated in all pneumonia
classes [HCAP, 22/199 (11.1%); HAP, 28/379 (7.4%); VAP, 57/606 (9.4%); p = 0.311]. Acinetobacter spp. were also
found with similar frequencies across pneumonia groups. To address potential enrollment bias toward patients
with MRSA pneumonia, we grouped patients by presence or absence of MRSA and found little difference in
frequencies of Pseudomonas and Acinetobacter.
Conclusions: In this population of pneumonia patients, the frequencies of MDR gram-negative pathogens were
similar among patients with HCAP, HAP, or VAP. Our data support inclusion of HCAP within nosocomial pneumonia
guidelines and the recommendation that empiric antibiotic regimens for HCAP should be similar to those for
HAP and VAP.
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Background
In 2005, the American Thoracic Society (ATS) and the
Infectious Diseases Society of America (IDSA) jointly
published guidelines for treatment of nosocomial pneu-
monia [1]. In addition to patients whose infections met
widely used definitions for hospital-acquired pneumonia
(HAP) and ventilator-associated pneumonia (VAP), these
guidelines identified an additional cohort of patients at
risk for potentially multidrug-resistant (MDR) pathogens,
those with healthcare-associated pneumonias (HCAP).
Criteria for HCAP include pneumonia associated with re-
cent hospitalization in an acute care hospital; residence in
a nursing home or extended care facility; or receipt of
chronic dialysis, home infusion therapy (including antibi-
otics), or home wound care. The guidelines suggest that
HCAP should be included in the spectrum of HAP and
VAP and that patients with HCAP be treated empirically
for MDR pathogens [1].
Support for the recommendation that patients with
HCAP should receive initial treatment active against
MDR pathogens has come predominantly from United
States–based studies that documented a high incidence
of these pathogens among patients with HCAP [2-8].
Recently, reports from several other countries have also
noted increased rates of MDR pathogens in hospitalized
patients with HCAP [9-17]. In contrast to these reports,
some investigators examining populations of patients
hospitalized for HCAP outside of the United States have
reported microbiologic patterns more closely resembling
those of community acquired pneumonia rather than
HAP and VAP [18-21]. This has led some to challenge
the use of the HCAP classification itself as well as any
associated treatment guidelines [22,23]. Alternatively,
the microbiology associated with these infections, and
thus the utility of the HCAP category, may vary with
geography or healthcare delivery systems.
Given this controversy and the importance of deter-
mining the appropriate initial therapy in these seriously
ill patients, we analyzed data from a large, international,
randomized, double-blind, controlled trial of patients
with nosocomial pneumonia and HCAP [24] to compare
baseline patient characteristics and microbiology find-
ings (including the relative incidence of infections with




This was a retrospective analysis of data from an in-
ternational, randomized, double-blind, multicenter trial
(ClinicalTrials.gov identifier NCT00084266) that com-
pared the efficacy and safety of linezolid and vancomycin
for the treatment of patients with nosocomial pneumonia
and HCAP due to methicillin-resistant Staphylococcus
aureus (MRSA). The details of this trial have been previ-
ously reported [24]. Briefly, from October 2004 through
January 2010 the study enrolled hospitalized patients
aged ≥ 18 years with radiographic and clinical signs of
pneumonia consistent with either nosocomial pneumonia
or HCAP. The study was approved by an Institutional Re-
view Board or Ethics Committee at each investigational
site. The list of investigators and the corresponding Ethics
Committees or Institutional Review Boards for this study
can be found in an Additional file 1: Figure S1. Written in-
formed consent was obtained from all patients or their le-
gally authorized representative [24]. The intent-to-treat
(ITT) population, which included all randomized patients
who received ≥ 1 dose of study drug, was used in this ana-
lysis. The population analyzed in this study included pa-
tients who were later found not to have MRSA infection
and who were excluded from the principal analysis in the
report of trial results. Of the 156 enrolling centers, 90
were in the United States.
Pneumonia definitions
Pneumonia was diagnosed by the combination of clinical
signs and symptoms, along with a new or evolving infil-
trate evident on chest imaging [24]. VAP was defined as
onset of pneumonia after > 48 hours of mechanical ven-
tilation, which was calculated by the sponsor from the
data available in the case report form. Nosocomial pneu-
monia cases occurring after at least 48 hours of hos-
pitalization that did not qualify as VAP were classified as
HAP. Initially, the study only enrolled patients with pneu-
monias meeting these criteria. After publication of the
ATS/IDSA guidelines in 2005, the study was amended to
permit enrollment of patients with HCAP that did not
qualify as VAP or HAP. For the trial, a slightly restrictive
definition of HCAP was employed: pneumonia acquired
in a long-term care or subacute/intermediate healthcare
facility (e.g. nursing home, rehabilitation center); pneumo-
nia following recent hospitalization (discharged within
90 days of current admission and previously hospitalized
for ≥ 48 hours); or pneumonia in patient who received
chronic dialysis care within 30 days prior to study enroll-
ment. This trial did not enroll patients with pneumonia
who only met the ATS/IDSA criteria for HCAP by virtue
of having recently received home infusion therapy or
wound care or of having a family member with an MDR
pathogen.
Assessments
Baseline demographic and clinical data were collected
including age, sex, race, and comorbidities. Patients were
required to have a baseline respiratory or sputum speci-
men prior to study enrollment or within 24 hours after
first dose of study medication. Microbiologic cultures
were performed according to the standard of care at the
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study site, except for patients with chronic ventilation
(> 30 days) or tracheostomy, for whom invasive quantita-
tive cultures were mandated. Patients were followed up to
30 days from the date of study enrollment. In keeping with
ATS/IDSA guidelines, we considered MRSA, Pseudo-
monas aeruginosa, and Acinetobacter spp. to be poten-
tially MDR pathogens.
Statistical analysis
All statistical tests were two-sided. To assess statistical
differences in the distribution of baseline characteristics
between pneumonia groups, one-way analysis of variance
was used for continuous variables, and chi-square test was
used for categorical variables. P values < 0.05 were consid-
ered statistically significant. Statistical procedures were
conducted using SAS, version 8.2 (SAS Institute, Inc.,
Cary, NC, USA).
Results
The ITT population included 1184 adult patients, of
whom 199 presented with HCAP, 379 with HAP, and
606 with VAP. Compared with those with HAP and
VAP, patients with HCAP were older and more likely to
have diabetes and cardiac, pulmonary, or renal comor-
bidities (Table 1). HCAP patients also had slightly higher
baseline Acute Physiology and Chronic Health Evaluation
(APACHE) II scores at the time of diagnosis of pneumo-
nia. Investigators from the United States enrolled 60.2% of
all patients in the trial and 87.4% of patients diagnosed
with HCAP.
The distribution of pathogens by pneumonia group is
reported in Table 2. The majority of identified organisms
were gram-positive, a finding consistent among HCAP,
HAP, and VAP patients. Most of these were MRSA
[HCAP, 82/199 (41.2%); HAP, 125/379 (33.0%); VAP,
259/606 (42.7%); p = 0.008 for difference between
groups]. Gram-negative organisms were cultured from
approximately one-third of patients, with P. aeruginosa
being the most common gram-negative organism in all
three pneumonia classes [HCAP, 22/199 (11.1%); HAP,
28/379 (7.4%); VAP, 57/606 (9.4%); p = 0.311]. The other
potentially MDR gram-negative species, Acinetobacter,
was somewhat less common but presented with similar
frequencies across pneumonia groups [HCAP, 8/199
(4.0%); HAP, 16/379 (4.2%); VAP, 44/606 (7.3%); p =
0.071]. Most patients had more than one potential pneu-
monia pathogen cultured, a finding that did not vary
with pneumonia type. Among the 689 patients with
more than one potential pneumonia pathogen identified,
57.2% had more than one gram-positive species, 5.1%
had more than one gram-negative species, and 37.3%
had both gram-positive and gram-negative species on cul-
ture. Bacteremia rates were similar among pneumonia
groups and comparable to rates reported in other
series [25,26].
Because the primary focus of the clinical trial was a
comparison of therapies for MRSA pneumonia, recruit-
ment efforts may have been directed toward patients
thought to be at increased risk for MRSA infection. As a
result, the enrolled population may not be representative
of the complete HCAP, HAP, and VAP populations
where the study was conducted. To address this poten-
tial bias, we divided enrolled patients by pneumonia
classification and presence or absence of MRSA, com-
paring the frequencies of P. aeruginosa and Acinetobac-
ter among the groups (Table 3). Assuming the true
population frequencies of P. aeruginosa and Acinetobac-
ter lie between those observed in the MRSA-infected
and non-infected groups, there is little difference by
pneumonia classification.
The all-cause mortality at day 28 was similar among
groups [HCAP, 25/199 (12.6%); HAP, 35/379 (9.2%);
VAP, 83/606 (13.7%); p = 0.11].




HCAP HAP VAP p value
(n = 199) (n = 379) (n = 606)
Age, y, mean (SD) 69.5 (13.4) 63.3 (15.8) 55.8 (19.8) < 0.001
Male, n (%) 117 (58.8) 247 (65.2) 411 (67.8) 0.067
APACHE II, mean (SD) 18.7 (6.4) 16.1 (6.3) 17.8 (5.7) < 0.001
Race, n (%) < 0.001
White 151 (75.9) 217 (57.3) 429 (70.8)
Black 25 (12.6) 28 (7.4) 72 (11.9)
Asian 18 (9.1) 97 (25.6) 56 (9.2)
Other 5 (2.5) 37 (9.8) 49 (8.1)
Region, n (%) < 0.001
United States 174 (87.4) 163 (43.0) 376 (62.1)
Europe 6 (3.0) 51 (13.5) 84 (13.9)
Latin America 2 (1.0) 43 (11.4) 78 (12.9)
Asia 14 (7.0) 93 (24.5) 49 (8.1)
Other 3 (1.5) 29 (7.7) 19 (3.1)
Comorbidities, n (%)
Cardiac 153 (76.9) 198 (52.2) 359 (59.2) < 0.001
Pulmonary 164 (82.4) 186 (49.1) 387 (63.9) < 0.001
Renal/Urinary 110 (55.3) 127 (33.5) 194 (32.0) < 0.001
Diabetes 98 (49.3) 128 (33.8) 198 (32.7) < 0.001
Vascular 74 (37.2) 109 (28.8) 187 (30.9) 0.111
Neoplastic 23 (11.6) 68 (17.9) 42 (6.9) < 0.001
Hepatobiliary 17 (8.5) 42 (11.1) 91 (15.0) 0.031
APACHE, Acute Physiology and Chronic Health Evaluation; HAP, Hospital-acquired
pneumonia; HCAP, Healthcare-associated pneumonia; VAP, Ventilator-associated
pneumonia.
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Discussion
We found that in a population of patients with nosocomial
pneumonia enrolled in a large, international, randomized,
double-blind trial of therapies for MRSA, the frequencies
of potentially MDR gram-negative pathogens were similar
among patients with pneumonia classified as HCAP, HAP,
or VAP. This suggests that, as recommended in ATS/
IDSA guidelines [1] empiric antibiotic regimens utilized
for patients hospitalized with HCAP should be similar
to those for HAP and VAP.
It is widely accepted that pneumonia occurring after
initiation of mechanical ventilation should initially be
treated with antibiotics active against MDR pathogens.
The rationale is straightforward: ventilated patients are
cared for in settings with high antibiotic utilization and
often receive antibiotics for other reasons. Both factors
contribute to the selection of MDR pathogens when
pneumonia occurs. Epidemiologic data in turn provide
empiric support for these recommendations [27,28].
Though these rationales and supporting epidemiologic
data are somewhat less compelling for pneumonias ac-
quired in the hospital under circumstances other than
mechanical ventilation, the extrapolation of VAP regi-
mens to HAP patients has been widely recommended
[1,29,30] and generally accepted.
In contrast, recommendations to use antibiotic combi-
nations originally chosen for VAP for patients with HCAP
have met with more controversy [19], with some arguing
that the HCAP classification itself lacks utility [22]. Our
findings speak to both questions. Patients with HCAP
were similar to those with HAP and VAP in several key re-
spects: severity of illness; microbiology, particularly the
frequency of potentially MDR pathogens; incidence of
bacteremia; and short-term mortality. On the other hand,
the higher burden of chronic conditions observed among
HCAP patients in this study may justify its being a separ-
ate classification, particularly for investigators examining
factors other than pathogen distribution.
Our study has several limitations. Most importantly,
rather than a survey of incident pneumonias, our data
derive from a population recruited because of its per-
ceived MRSA risk. Investigators may have taken into
consideration factors not accounted for in the collected
data that differentiate enrolled patients from other patients
with VAP, HAP, and HCAP; e.g. airway specimen gram
stain results, history of MRSA colonization, and even in-
fections and colonization of nearby patients. If study inves-
tigators intended to enroll patients with MRSA infection,
they indeed succeeded, selecting a population with a
prevalence of MRSA exceeding that commonly reported
[2,31-33]. We feel data from this study therefore should
not be used to compare MRSA risk among pneumonia
groups. Rather, our analysis focuses on the prevalence
of potentially MDR gram-negative organisms, potential
Table 2 Microbiology grouped by HCAP, HAP, and VAPa
Microbiology HCAP HAP VAP
(n = 199) (n = 379) (n = 606)
n (%) n (%) n (%)
Gram-positive pathogens 117 (58.8) 226 (59.6) 441 (72.8)
MRSA 82 (41.2) 125 (33.0) 259 (42.7)
MSSA 12 (6.0) 51 (13.5) 107 (17.7)
Pneumococcus 4 (2.0) 10 (2.6) 15 (2.5)
Other Streptococcus spp. 7 (3.5) 15 (4.0) 18 (3.0)
Gram-negative pathogens 53 (26.6) 113 (29.8) 222 (36.6)
Pseudomonas aeruginosa 22 (11.1) 28 (7.4) 57 (9.4)
Acinetobacter spp. 8 (4.0) 16 (4.2) 44 (7.3)
Haemophilus spp. 6 (3.0) 5 (1.3) 23 (3.8)
Moraxella catarrhalis 4 (2.0) 1 (0.3) 2 (0.3)
Klebsiella spp. 5 (2.5) 32 (8.4) 41 (6.8)
Escherichia coli 10 (5.0) 19 (5.0) 17 (2.8)
Enterobacter spp. 3 (1.5) 15 (4.0) 31 (5.1)
Proteus mirabilis 1 (0.5) 8 (2.1) 13 (2.1)
Stenotrophomonas maltophilia 0 (0) 2 (0.5) 13 (2.1)
Polymicrobial 111 (55.8) 191 (50.4) 387 (63.9)
Culture negative 50 (25.1) 101 (26.6) 79 (13.0)
Bacteremia 28 (14.1) 49 (12.9) 103 (17.0)
HAP, Hospital-acquired pneumonia; HCAP, Healthcare-associated pneumonia;
MRSA, Methicillin-resistant Staphylococcus aureus; MSSA, Methicillin-susceptible
S. aureus; VAP, Ventilator-associated pneumonia.
aMost commonly isolated pathogens reported (at least 2% in HCAP, HAP,
or VAP).
Table 3 Frequency distribution of Pseudomonas aeruginosa and Acinetobacter spp. by pneumonia classification and
presence or absence of MRSA
HCAP HAP VAP
No MRSA MRSA No MRSA MRSA No MRSA MRSA
(n = 117) (n = 82) (n = 254) (n = 125) (n = 347) (n = 259)
n (%) n (%) n (%) n (%) n (%) n (%)
Pseudomonas aeruginosa 14 (12.0) 8 (9.8) 18 (7.1) 10 (8.0) 30 (8.6) 27 (10.4)
Acinetobacter spp. 5 (4.3) 3 (3.7) 8 (3.1) 8 (6.4) 20 (5.8) 24 (9.3)
HAP, Hospital-acquired pneumonia; HCAP, Healthcare-associated pneumonia; MRSA, Methicillin-resistant Staphylococcus aureus; VAP, Ventilator-associated pneumonia.
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pathogens that the study was not seeking, and the agents
under study do not treat. Distributions of potentially MDR
gram-negative organisms were similar among patients with
VAP, HAP, or HCAP and varied little with the presence or
absence of MRSA.
That the study design should enhance recruitment of
patients with gram-negative pathogens is certainly not
obvious. Patients without MRSA were not permitted to
complete the clinical trial, and investigator knowledge of
certain specific gram-negative risk factors (gram stain re-
sults, colonization history, or local ecology) would likely
discourage enrollment of patients with gram-negative in-
fections. On the other hand, to the extent that investi-
gators believed that risk factors for MRSA and MDR
gram-negative pathogens are similar, efforts to enhance
MRSA pneumonia recruitment might also have increased
the prevalence of gram-negative pathogens in our sample.
In either case, we have little reason to expect that such
biases differed by pneumonia class. Our key finding thus
seems robust: the likelihood of MDR gram-negative path-
ogens being present in HCAP is similar to that in HAP
and VAP, pneumonias for which coverage of these organ-
isms is widely accepted.
As is always the case in studies that do not obtain tis-
sue to confirm the presence of pneumonia histopatho-
logically, diagnoses and causative microbiology cannot
be established with certainty [34]. It is possible that in
many cases potentially pathogenic bacteria were merely
colonizers, particularly when multiple potential patho-
gens were found in the same patient. We know of no
reason why this would be more likely in HCAP than in
HAP or VAP. To the contrary, we suspect colonization
is a more frequent phenomenon among patients with
VAP, whose airways are instrumented. In any case, dis-
tinguishing true pathogens from colonizers in clinical
practice is challenging; a commonly adopted strategy is
therefore to treat all isolated organisms reasonably likely
to be pathogens. Empiric regimens for HCAP should
therefore be as broad in spectrum as those for HAP and
VAP.
Geography may play an important role in our findings.
HCAP patients were enrolled disproportionately in the
United States. Possible interpretations include physicians
outside the United States not recognizing patients with
HCAP as being at risk for MRSA and so not considering
them for enrollment; HCAP being more common in the
United States than elsewhere; or investigator access to
patients with HCAP varying by country. It seems clear
that empiric antibiotics for HCAP in the United States
should cover MDR pathogens. Given the possible dif-
ferences in HCAP incidence across geographic regions,
we would be hesitant to assume that the microbiology,
and hence recommended treatments, should not also
vary with location.
Conclusions
In summary, we compared important demographic char-
acteristics and associated pathogens among patients with
HCAP, HAP, or VAP recruited into a large, international
pneumonia study. HCAP patients were older and had
more comorbidities, higher APACHE II scores, and
comparable short-term mortality compared with patients
with HAP or VAP. The prevalence of potentially MDR
organisms, particularly gram-negatives, was similar across
groups, lending support to the recommendation that
initial empiric antibiotic therapy should be similar in all
groups and should include agents with activity against
these pathogens.
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